Navigation Links
Lotus Pharmaceuticals Announces Conference Call to Discuss Second Quarter 2008 Results
Date:8/13/2008

BEIJING, Aug. 13 /Xinhua-PRNewswire-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the "Company"), a pharmaceutical company in the People's Republic of China ("PRC"), today announced that it will conduct a conference call at 10:00 a.m. Eastern Time on Monday, August 18, 2008 to discuss results for the quarter ended June 30, 2008.

Joining Dr. Zhongyi Liu, Chairman and Chief Executive Officer of Lotus Pharmaceuticals, will be Mr. Adam Wasserman, Chief Financial Officer.

To participate in this live conference call, please dial 888-481-7939 five to ten minutes prior to the scheduled conference call time. International callers should dial 617-847-8707. The conference Passcode is 306 650 22.

For those who are unable to participate in the conference call at the time of the call, a replay will be available for fourteen days starting on August 18, at 12:00 p.m. Eastern Time. To access the replay, please dial 888-286- 8010. International callers should dial 617-801-6888. The replay Passcode is 939 152 01.

About Lotus Pharmaceuticals, Inc.

Lotus Pharmaceuticals, Inc. controls and operates Liangfang Pharmaceutical Company, Ltd. ("Liang Fang") and En Ze Jia Shi Pharmaceutical Company, Ltd. ("En Ze"), two pharmaceutical companies located in Beijing, China. Together, Liang Fang and En Ze form an operating company (together, "Lotus East"). Lotus East engages in the development of new drugs, drug manufacturing, and the marketing and sales of pharmaceuticals. Lotus East has advanced pharmaceutical production equipment with which it produces a portfolio of pharmaceutical products, and meets National GMP. Lotus East has a number of highly skilled scientists, 2,000 square meters of office space and a 1,000 square meter warehouse. It operates ten retail pharmacies in the Beijing area.

Safe Harbor Statement

This press release contains "forward-looking statements" within the meaning of the "safe-harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including changes from anticipated levels of sales, future national or regional economic and competitive and regulatory conditions, changes in relationships with customers, access to capital, difficulties in developing and marketing new products, marketing existing products, customer acceptance of existing and new products, and other factors. Additional information regarding risks can be found in the Company's Annual Report on Form 10K filed with the SEC. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company has no obligation to update the forward-looking information contained in this press release.

For more information, please contact:

Lotus Pharmaceuticals, Inc.

Mr. Adam Wasserman, CFO

Tel: +1-877-801-0344

Email: info@LotusEast.com

Web site: http://www.lotuseast.com

CCG Investor Relations Inc.

Mr. Crocker Coulson, President

Tel: +1-646-213-1915 (New York)

Email: crocker.coulson@ccgir.com

Web site: http://www.ccgir.com


'/>"/>
SOURCE Lotus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Lotus Pharmaceuticals, Inc. Reaffirms its Confidence in Meeting its Make Good Target for Fiscal Year 2008
2. Lotus Pharmaceuticals, Inc. Announces Conference Call to Discuss First Quarter 2008 Results
3. Lotus Pharmaceuticals, Inc. Announces Resignation of Director Mel Rothberg
4. Lotus Pharmaceuticals, Inc. Announces Fourth Quarter and Fiscal Year 2007 Results
5. Lotus Pharmaceuticals, Inc. Announces Conference Call to Discuss Fourth Quarter and Fiscal Year 2007 Results
6. Lotus Pharmaceuticals Raises $5 Million in Private Placement
7. Lotus Pharmaceuticals, Inc. Implements Environmentally-friendly Cost Saving Strategies
8. Lotus Blossom Consulting Announces E-Book on Infertility Treatment Financing
9. MAP Pharmaceuticals Reports Second Quarter of 2008 Financial Results
10. Triax Pharmaceuticals Launches New Mid-Potency Corticosteroid Vehicle, Locoid Lotion 0.1%
11. ADVENTRX Pharmaceuticals Reports Second Quarter 2008 Financial Results and Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... ... , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize ... Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into ... Simply select a ProHand generator and drag it above media or text in the ...
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
(Date:6/25/2016)... ... 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland ... iHire in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness ... & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical Systems ... "Company"), which develops, markets and sells medical devices and ... , signed a strategic cooperation agreement with Hongyuan Supply ... Supply Chain") on June 20, 2016, to develop Dehaier,s ... strategic cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s ...
(Date:6/24/2016)... June 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... innovative inhaled drugs, announced today that it was added ... reconstituted its comprehensive set of U.S. and global ... is an important milestone for Pulmatrix," said Chief Executive ... awareness of our progress in developing drugs for crucial ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
Breaking Medicine Technology: